AVC-201

N/A

Report date: 2024/03/26 18:00:52

Base Information

Drug NameAVC-201

Drug Alias NameAVC-201Allo-RevCAR01-T-CD123

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD123

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAvenCell Europe GmbH

China Registration ClassN/A

Develop Information

Active CompaniesAvenCell Europe GmbH

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A